bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) has been researched along with Hematologic Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dragovich, T; Hoos, A; Kurtin, S; Mendelson, D; Richardson, K; Von Hoff, D | 1 |
| Khokhar, AR; Lautersztain, J; Perez-Soler, R; Stephens, LC; Wright, K | 1 |
1 trial(s) available for bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) and Hematologic Diseases
| Article | Year |
|---|---|
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Hematologic Diseases; Humans; Hyperbilirubinemia; Liposomes; Male; Middle Aged; Nausea; Neoplasm Staging; Organoplatinum Compounds; Peripheral Nervous System Diseases; Treatment Outcome; Vomiting | 2006 |
1 other study(ies) available for bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) and Hematologic Diseases
| Article | Year |
|---|---|
Preclinical toxicity and pharmacology of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).
Topics: Animals; Antineoplastic Agents; Dogs; Drug Evaluation, Preclinical; Half-Life; Hematologic Diseases; Intestines; Kidney; Lethal Dose 50; Liposomes; Liver; Mice; Organoplatinum Compounds; Stomach | 1989 |